IQ continues to grow as an organization and advance key industry initiatives while delivering innovative approaches and effective therapies to patients. We look forward to mutually beneficial collaboration and progress of our portfolio to ensure that the mission of IQ is achieved.
WASHINGTON (PRWEB)
September 12, 2022
The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium) announced the joining of six (6) new member companies at its recent Board of Directors meeting. The new members are Novo Nordisk, The Bill and Melinda Gates Medical Research Institute, Relay Therapeutics, Xencor, CSL Behring, and Idorsia. This brings the IQ Consortium membership to 44 companies.
Margaret Faul, the consortium Chair, said that “it is exciting to welcome new members to the IQ Consortium. Our members are committed to creative and generous industry collaboration. IQ continues to grow as an organization and advance key industry initiatives while delivering innovative approaches and effective therapies to patients. We look forward to mutually beneficial collaboration and progress of our portfolio to ensure that the mission of IQ is achieved.”
ABOUT THE NEW MEMBER COMPANIES
Novo Nordisk is a global healthcare company developing innovative therapies for patients with diabetes, obesity, and other serious chronic diseases. Novo Nordisk will be represented on the IQ Board of Directors by Søren Thuesen Pedersen and Peter Ravn Brinck.
The Bill & Melinda Gates Medical Research Institute is a non-profit organization committed to developing and deploying novel biomedical interventions for TB, malaria, diarrheal diseases, maternal and child illnesses, and other global health concerns. The Bill & Melinda Gates Medical Research Institute will be represented on the IQ Board of Directors by Monicah Otieno and Micha Levi.
Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process. Their platform integrates computational and experimental approach to advance therapies focusing on precision oncology and genetic disease. Relay Therapeutics will be represented on the IQ Board of Directors by Mahesh Padval.
Xencor is using its protein engineering platform to develop a broad pipeline of antibody and cytokine drugs that are optimized to treat patients with cancer and autoimmune disorders. Xencor will be represented on the IQ Board of Directors by Norman Barlow and Jitendra Kanodia.
CSL Behring is a leading global biotech company driven by its promise to save and improve lives by manufacturing plasma-derived and recombinant therapeutic products for serious and rare diseases. CSL Behring will be represented on the IQ Board of Directors by Silpa Nuthalapati and Jason Newman.
Idorsia is a biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative small molecules. Their development pipeline covers multiple therapeutic areas such as insomnia, cerebral vasospasm, resistant hypertension, and lupus. Idorsia will be represented on the IQ Board of Directors by Olivier Lambert and Markus Von Raumer.
The IQ Consortium is proud to have these innovative companies join the consortium and looks forward to further collaboration in the pursuit of pharmaceutical development, technical innovation, and continued service to patients.
UPCOMING IQ EVENTS
In October, the IQ Consortium is hosting the annual CMC Summit as well as the IQ Symposium. Membership is not required to attend. Visit the IQ website to register and find out more information about these events.
About the IQ Consortium
The IQ Consortium is a not-for-profit organization of pharmaceutical and biotechnology companies with a mission of advancing science and technology to augment the capability of member companies to develop transformational solutions that benefit patients, regulators, and the broader research and development community. Learn more at http://www.iqconsortium.org.
Media Contact:
IQ Secretariat
info@iqconsortium.org
Share article on social media or email: